Abraxis BioScience, LLC
82Patents
79Active
82Granted
58Portfolio score
Filing activity: Dec 23, 2004 → Feb 14, 2024 · 30 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7820788B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 161 | Active |
| US8138229B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 146 | Active |
| US7923536B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 131 | Active |
| US8314156B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 128 | Active |
| US8034375B2 | Combinations and modes of administration of therapeutic agents and combination therapy | Human Necessities | 125 | Active |
| US7758891B2 | Combinations and modes of administration of therapeutic agents and combination therapy | Human Necessities | 117 | Active |
| US8735394B2 | Combinations and modes of administration of therapeutic agents and combination therapy | Human Necessities | 114 | Active |
| US8268348B2 | Combinations and modes of administration of therapeutic agents and combination therapy | Human Necessities | 107 | Active |
| US8034765B2 | Compositions and methods for preparation of poorly water soluble drugs with increased stability | Emerging Cross-Sectional Technologies | 102 | Active |
| US8853260B2 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | Human Necessities | 99 | Active |
| US9101543B2 | Combinations and modes of administration of therapeutic agents and combination therapy | Human Necessities | 90 | Active |
| US7771751B2 | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents | Emerging Cross-Sectional Technologies | 62 | Active |
| US7981445B2 | Compositions and methods for preparation of poorly water soluble drugs with increased stability | Emerging Cross-Sectional Technologies | 58 | Active |
| US8911786B2 | Nanoparticle comprising rapamycin and albumin as anticancer agent | Human Necessities | 57 | Active |
| US7780984B2 | Methods and compositions for treating proliferative diseases | Human Necessities | 53 | Active |
| US7858782B2 | Triazine derivatives and their therapeutical applications | Chemistry; Metallurgy | 51 | Active |
| US8257733B2 | Methods and compositions for treating proliferative diseases | Human Necessities | 49 | Active |
| US8846771B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 48 | Active |
| US8137684B2 | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof | Human Necessities | 47 | Active |
| US9149455B2 | Methods of treating melanoma | Human Necessities | 42 | Active |
| US9511046B2 | Methods of treating pancreatic cancer | Human Necessities | 42 | Active |
| US8927019B2 | Methods and compositions for treating recurrent cancer | Emerging Cross-Sectional Technologies | 38 | Active |
| US8999396B2 | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane | Human Necessities | 38 | Active |
| US9061014B2 | Intravascular delivery of nanoparticle compositions and uses thereof | Human Necessities | 37 | Active |
| US9012519B2 | Compositions and methods of delivery of pharmacological agents | Emerging Cross-Sectional Technologies | 36 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.